Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 29
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Peroxidase (POD) Mimicking Activity of Different Types of Poly(ethyleneimine)-Mediated Prussian Blue Nanoparticles

  • Gunatilake, Udara Bimendra|||0000-0002-3389-5520
  • Pérez-López, Briza
  • Urpí Fernández, Ana María|||0000-0002-2446-1077
  • Prat-Trunas, Judit
  • Carrera i Cardona, Gerard|||0000-0001-6111-0594
  • Félix, Gautier|||0000-0002-2761-6353
  • Sene, Saad|||0000-0002-2542-3881
  • Beaudhuin, Mickaël|||0000-0002-2568-546X
  • Dupin, Jean-Charles
  • Allouche, Joachim
  • Guari, Yannick|||0000-0001-5205-3225
  • Larionova, Joulia
  • Baldrich Rubio, Eva|||0000-0003-1393-215X
Prussian blue nanoparticles (PBNPs) have been identified as a promising candidate for biomimetic peroxidase (POD)-like activity, specifically due to the metal centres (Fe 3+ /Fe 2+) of Prussian blue (PB), which have the potential to function as catalytically active centres. The decoration of PBNPs with desired functional polymers (such as amino- or carboxylate-based) primarily facilitates the subsequent linkage of biomolecules to the nanoparticles for their use in biosensor applications. Thus, the elucidation of the catalytic POD mimicry of these systems is of significant scientific interest but has not been investigated in depth yet. In this report, we studied a series of poly(ethyleneimine) (PEI)-mediated PBNPs (PB/PEI NPs) prepared using various synthesis protocols. The resulting range of particles with varying size (~19-92 nm) and shape combinations were characterised in order to gain insights into their physicochemical properties. The POD-like nanozyme activity of these nanoparticles was then investigated by utilising a 3,3',5,5'-tetramethylbenzidine (TMB)/HO system, with the catalytic performance of the natural enzyme horseradish peroxidase (HRP) serving as a point of comparison. It was shown that most PB/PEI NPs displayed higher catalytic activity than the PBNPs, with higher activity observed in particles of smaller size, higher Fe content, and higher Fe 2+ /Fe 3+ ratio. Furthermore, the nanoparticles demonstrated enhanced chemical stability in the presence of acid, sodium azide, or high concentrations of HO when compared to HRP, confirming the viability of PB/PEI NPs as a promising nanozymatic material. This study disseminates fundamental knowledge on PB/PEI NPs and their POD-like activities, which will facilitate the selection of an appropriate particle type for future biosensor applications.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cofactors facilitate bona fide prion misfolding in vitro but are not necessary for the infectivity of recombinant murine prions

  • Pérez-Castro, Miguel Ángel
  • Eraña, Hasier|||0000-0001-8776-4211
  • Vidal Barba, Enric|||0000-0002-4965-3286
  • Charco, Jorge M.|||0000-0003-3476-1855
  • Lorenzo, Nuria L.
  • Gonçalves-Anjo, Nuno|||0000-0003-0586-2550
  • Galarza-Ahumada, Josu|||0000-0003-0275-559X
  • Díaz-Domínguez, Carlos M.|||0000-0002-0410-1963
  • Piñeiro, Patricia|||0000-0002-0062-2542
  • González-Miranda, Ezequiel
  • Giler, Samanta
  • Telling, Glenn
  • Sánchez-Martín, Manuel A.|||0000-0001-8370-1336
  • Garrido, Joseba M.
  • Geijo, Maria V.|||0000-0002-3120-1038
  • Requena, Jesús R.
  • Castilla, Joaquín|||0000-0002-2216-1361
Prion diseases, particularly sporadic cases, pose a challenge due to their complex nature and heterogeneity. The underlying mechanism of the spontaneous conversion from PrP C to PrP Sc, the hallmark of prion diseases, remains elusive. To shed light on this process and the involvement of cofactors, we have developed an in vitro system that faithfully mimics spontaneous prion misfolding using minimal components. By employing this PMSA methodology and introducing an isoleucine residue at position 108 in mouse PrP, we successfully generated recombinant murine prion strains with distinct biochemical and biological properties. Our study aimed to explore the influence of a polyanionic cofactor in modulating strain selection and infectivity in de novo -generated synthetic prions. These results not only validate PMSA as a robust method for generating diverse bona fide recombinant prions but also emphasize the significance of cofactors in shaping specific prion conformers capable of crossing species barriers. Interestingly, once these conformers are established, our findings suggest that cofactors are not necessary for their infectivity. This research provides valuable insights into the propagation and maintenance of the pathobiological features of cross-species transmissible recombinant murine prion and highlights the intricate interplay between cofactors and prion strain characteristics. Prion diseases are rare and complex neurodegenerative disorders that can occur spontaneously, through a poorly understood conformational or structural change of normal, physiological prion protein. This abnormally structured form, known as prion, acquires the capacity to induce the same transformation to surrounding prion proteins, leading to disease. In our study, we take advantage of a recently developed methodology that closely mimics this process in a test tube using extremely simple components. Applying this system and modifying a specific part of the mouse prion protein, we were able to generate different prion strains with unique characteristics spontaneously. This process is greatly enhanced using an additional molecule called cofactor, that has been proposed to affect the variability and infectivity (capacity to cause disease in an animal model) of these prions. Our findings show that while cofactors facilitate the spontaneous formation of prions and may influence their final characteristics, they are not necessary for their infectivity nor for their spontaneous formation. This research gives new insights into the role cofactors play in the spontaneous generation of prions and their behavior in animal models.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort

  • Toapanta, Néstor|||0000-0001-5983-6863
  • Comas, Jordi|||0000-0001-5257-7029
  • Revuelta, Ignacio|||0000-0002-3584-4516
  • Manonelles, Anna|||0000-0003-2456-388X
  • Facundo, Carme|||0000-0003-1254-5553
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Vila, Anna
  • Arcos, Emma
  • Tort, Jaume
  • Giral, Magali|||0000-0001-7641-1592
  • Naesens, Maarten|||0000-0002-5625-0792
  • Kuypers, Dirk RJ.|||0000-0001-5546-9680
  • Åsberg, Anders|||0000-0002-0628-1769
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Although kidney transplantation from living donors (LD) offers better long-term results than from deceased donors (DD), elderly recipients are less likely to receive LD transplants than younger ones. We analyzed renal transplant outcomes from LD versus DD in elderly recipients with a propensity-matched score. This retrospective, observational study included the first single kidney transplants in recipients aged ≥65 years from two European registry cohorts (2013-2020, n = 4,257). Recipients of LD (n = 408), brain death donors (BDD, n = 3,072), and controlled cardiocirculatory death donors (cDCD, n = 777) were matched for donor and recipient age, sex, dialysis time and recipient diabetes. Major graft and patient outcomes were investigated. Unmatched analyses showed that LD recipients were more likely to be transplanted preemptively and had shorter dialysis times than any DD type. The propensity score matched Cox's regression analysis between LD and BDD (387-pairs) and LD and cDCD (259-pairs) revealing a higher hazard ratio for graft failure with BDD (2.19 [95% CI: 1.16-4.15], p = 0.016) and cDCD (3.38 [95% CI: 1.79-6.39], p < 0.001). One-year eGFR was higher in LD transplants than in BDD and cDCD recipients. In elderly recipients, LD transplantation offers superior graft survival and renal function compared to BDD or cDCD. This strategy should be further promoted to improve transplant outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Understanding the key features of the spontaneous formation of bona fide prions through a novel methodology that enables their swift and consistent generation

  • Eraña, Hasier|||0000-0001-8776-4211
  • Díaz-Domínguez, Carlos M.|||0000-0002-0410-1963
  • Charco, Jorge M.|||0000-0003-3476-1855
  • Vidal Barba, Enric|||0000-0002-4965-3286
  • González-Miranda, Ezequiel
  • Pérez-Castro, Miguel A.|||0000-0003-2850-3470
  • Piñeiro, Patricia|||0000-0002-0062-2542
  • López-Moreno, Rafael
  • Sampedro-Torres-Quevedo, Cristina|||0000-0001-6374-1760
  • Fernández-Veiga, Leire
  • Tasis-Galarza, Juan
  • Lorenzo, Nuria L.
  • Santini-Santiago, Aileen
  • Lázaro, Melisa
  • García-Martínez, Sandra|||0000-0002-6910-9202
  • Gonçalves-Anjo, Nuno|||0000-0003-0586-2550
  • San-Juan-Ansoleaga, Maitena|||0000-0001-7968-510X
  • Galarza-Ahumada, Josu|||0000-0003-0275-559X
  • Fernández-Muñoz, Eva
  • Giler, Samanta
  • Valle, Mikel
  • Telling, Glenn C.
  • Geijó, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín|||0000-0002-2216-1361
Among transmissible spongiform encephalopathies or prion diseases affecting humans, sporadic forms such as sporadic Creutzfeldt-Jakob disease are the vast majority. Unlike genetic or acquired forms of the disease, these idiopathic forms occur seemingly due to a random event of spontaneous misfolding of the cellular PrP (PrPC) into the pathogenic isoform (PrPSc). Currently, the molecular mechanisms that trigger and drive this event, which occurs in approximately one individual per million each year, remain completely unknown. Modelling this phenomenon in experimental settings is highly challenging due to its sporadic and rare occurrence. Previous attempts to model spontaneous prion misfolding in vitro have not been fully successful, as the spontaneous formation of prions is infrequent and stochastic, hindering the systematic study of the phenomenon. In this study, we present the first method that consistently induces spontaneous misfolding of recombinant PrP into bona fide prions within hours, providing unprecedented possibilities to investigate the mechanisms underlying sporadic prionopathies. By fine-tuning the Protein Misfolding Shaking Amplification method, which was initially developed to propagate recombinant prions, we have created a methodology that consistently produces spontaneously misfolded recombinant prions in 100% of the cases. Furthermore, this method gives rise to distinct strains and reveals the critical influence of charged surfaces in this process.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer, towards the clinical application

  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • Vilar, Ana
  • Cueva, Juan|||0000-0003-1389-4595
  • Arias, Efigenia
  • Sampayo, Victoria
  • Diaz, Eva
  • Oltra, Sara S.
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Cortegoso, Alexandra
  • Curiel, Teresa
  • Abalo, Alicia
  • Pamies Serrano, Mónica
  • Domingo, Santiago
  • Padilla-Iserte, Pablo
  • Arnaez de la Cruz, Marta
  • Hernández Gutierrez, Alicia|||0000-0002-2494-3041
  • García-Pineda, Virginia
  • Ruiz-Bañobre, Juan
  • López, Rafael
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Moreno-Bueno, Gema
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
There has been a rise in endometrial cancer (EC) incidence leading to increased mortality. To counter this trend, improving the stratification of post-surgery recurrence risk and anticipating disease relapse and treatment resistance is essential. Liquid biopsy analyses offer a promising tool for these clinical challenges, though the best strategy for applying them in EC must be defined. This study was designed to determine the value of cfDNA/ctDNA monitoring in improving the clinical management of patients with localized and recurrent disease. Plasma samples and uterine aspirates (UA) from 198 EC patients were collected at surgery and over time. The genetic landscape of UAs was characterized using targeted sequencing. Total cfDNA was analyzed for ctDNA presence based on the UA mutational profile. High cfDNA levels and detectable ctDNA at baseline correlated with poor prognosis for DFS (p-value < 0.0001; HR = 9.25) and DSS (p-value < 0.0001; HR = 11.20). This remained clinically significant when stratifying tumors by histopathological risk factors. Of note, cfDNA/ctDNA analyses discriminated patients with early post-surgery relapse and the ctDNA kinetics served to identify patients undergoing relapse before any clinical evidence emerged. This is the most comprehensive study on cfDNA/ctDNA characterization in EC, demonstrating its value in improving risk stratification and anticipating disease relapse in patients with localized disease. CtDNA kinetics assessment complements current strategies to monitor the disease evolution and the treatment response. Therefore, implementing cfDNA/ctDNA monitoring in clinical routines offers a unique opportunity to improve EC management. The study demonstrates that high levels of cfDNA and detectable ctDNA at baseline are strong indicators of poor prognosis. This enables more accurate risk stratification beyond traditional histopathological factors, allowing clinicians to identify high-risk patients who may benefit from more aggressive treatment and closer monitoring. Moreover, longitudinal analysis of cfDNA/ctDNA can detect disease recurrence months before clinical symptoms or imaging evidence appear. This early warning system offers a significant advantage in clinical practice, providing a window of opportunity for early intervention and potentially improving patient outcomes. The online version contains supplementary material available at 10.1186/s13046-024-03158-w.
Repositori Institucional UIB
Publicación Artículo científico (JournalArticle)

KLB and NOX4 expression levels as potential blood-based transcriptional biomarkers of physical activity in children.

  • Galmés, Sebastià
  • Rupérez, Azahara I.
  • Sánchez, Juana
  • Moreno, Luis A.
  • Foraita, Ronja
  • Hebestreit, Antge
  • Molnár, Dénes
  • Palou, Andreu
  • Picó, Catalina
[eng] Insufficient physical activity (PA) in children is considered one of the major contributors to obesity and cardiometabolic complications later in life. Although regular exercise may contribute to disease prevention and health promotion, reliable early biomarkers are required to objectively discern people performing low PA from those who exercise enough. Here, we aimed to identify potential transcript‑based biomarkers through the analysis of a whole‑genome microarray in peripheral blood cells (PBC) from physically less active (n = 10) comparing with more active (n = 10) children. A set of genes differentially expressed (p < 0.01, Limma test) in less physically active children were identified, including the down‑regulation of genes related to cardiometabolic benefits and improved skeletal function (KLB, NOX4, and SYPL2), and the up‑regulation of genes whose elevated expression levels are associated with metabolic complications (IRX5, UBD, and MGP). The analysis of the enriched pathways significantly affected by PA levels were those associated with protein catabolism, skeletal morphogenesis, and wound healing, among others, which may suggest a differential impact of low PA on these processes. Microarray analysis comparing children according to their usual PA has revealed potential PBC transcript‑based biomarkers that may be useful in early discerning children expending high sedentary time and its associated negative consequences.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Designing polyphosphazene derivatives for gene delivery in glioblastoma treatment

  • García Mazás, Carla
  • Bozzato, Elia
  • Araujo Fernández, Jhonathan Angel
  • Quattrini, Federico
  • Preat, Veronique
  • Sánchez Piñón, Laura
  • Csaba, Noemi Stefania
  • García Fuentes, Marcos
Gene therapy presents promising opportunities to target critical pathways in complex cancers like glioblastoma multiforme, though it necessitates the use of efficient delivery vectors. Polyphosphazenes (PPZs) are highly flexible materials that lead to biodegradable, high-performance materials in various applications, including gene delivery. In this work, we synthesized various PPZ derivatives, incorporating primary amines, secondary amines, hydrophilic, and hydrophobic groups, and evaluated their gene transfection capabilities in combination with an anionic polyphosphazene (6MHA-PPZ) that acts as a charge quencher and transfection enhancer. Combining 6MHA-PPZ with a hydrophobic polymer demonstrated the highest gene delivery efficiency and safety, significantly surpassing previous benchmarks. Using these optimized nanoparticles, we delivered a BMP4-expressing plasmid (pBMP4) in glioblastoma models. The pBMP4 nanoparticles, when combined with the chemotherapeutic agent temozolomide (Tz), resulted in significant reductions in tumor volume, improved survival rates in preclinical models, and normalized the expression of drug resistance markers, providing a synergistic antitumoral effect with Tz. This study highlights the potential of PPZ-based nanoparticles for gene delivery and suggests that the combination of pBMP4-NPs and Tz could offer a promising therapeutic strategy for treating glioblastoma.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Quantitative PET tracking of intra-articularly administered 89Zr-peptide-decorated nanoemulsions

  • Díez Villares, Sandra
  • García Varela, Lara
  • Groba de Antas, Soraya
  • Caeiro Rey, José Ramón
  • Carpintero-Fernandez, Paula
  • Mayán, María D.
  • Aguiar Fernández, Pablo
  • Fuente, María de la
Intra-articular (IA) administration of drugs for the treatment of diseases such as rheumatoid arthritis, osteoarthritis and psoriatic arthritis is a common strategy; however, the rapid clearance from the synovial fluid restricts their effectivity due to the limited retention time. Drug Delivery Systems (DDS) are currently being developed to increase their joint retention time. This study compares the biodistribution and retention time of a senolytic peptide (PEP), with potential application in osteoarthritis disease, and this senolytic peptide encapsulated in a DDS based on a lipid nanoemulsion (PEPsingle bondNE) by using positron emission tomography (PET) imaging. To this aim, the PEP was conjugated with a chelating agent (DFO) and radiolabeled with zirconium-89 (89Zr). Then, [89Zr]-PEP was encapsulated in a novel nanoemulsion formulation, composed by vitamin E, sphingomyelin, and a lipid-PEG. Afterward, healthy rats were administered with either the [89Zr]-PEP or the [89Zr]-PEP-NE via IA injection and underwent PET scans at 0.5-, 24-, 48-, 72-, 168-, 240- and 336 h post-injection. To assess the biodistribution of both radiotracers, several volume-of-interest were manually drawn in different organs of the rat body and the %ID/organ was calculated. The [89Zr]-PEP was successfully encapsulated in the NE and their physicochemical properties were minimally affected by the radiolabeling buffer. Adequate stability of both [89Zr]-PEP and [89Zr]-PEP-NE was found in synovial fluid over 72 h. Quantitative data from PET images revealed a significantly higher [89Zr]-PEP-NE retention in the injected knee than with [89Zr]-PEP in all follow-up PET scans. The [89Zr]-PEP %ID/organ values in the liver and kidney were significantly higher than those from [89Zr]-PEP-NE, which might indicate a faster elimination of the [89Zr]-PEP. Therefore, the study highlights the higher retention time on the target site of the [89Zr]-PEP-NE which may improve the therapeutic effects of the peptide. Thereby, the novel nanoemulsion formulation seems to be a successful DDS for IA injection. In addition, these results represent the first study that evaluates the distribution of a PET-guided DDS after its IA administration.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Conservation of strain properties of bank vole-adapted chronic wasting disease in the absence of glycosylation and membrane anchoring

  • Vidal, Enric
  • López Lorenzo, Nuria
  • Rodríguez Requena, Jesús
  • Castilla, Joaquín
Prion disease phenotypes (prion strains) are primarily determined by the specific misfolded conformation of the cellular prion protein (PrPC). However, post-translational modifications, including glycosyl phosphatidyl inositol (GPI) membrane anchoring and glycosylation, may influence strain characteristics. We investigated whether these modifications are essential for maintaining the unique properties of bank vole-adapted Chronic Wasting Disease (CWD-vole), the fastest known prion strain. Using a novel transgenic mouse model expressing I109 bank vole PrPC lacking the GPI anchor and largely devoid of glycans, we performed serial passages of CWD-vole prions. Despite elongated initial incubation periods, the strain maintained 100 % attack rate through three passages. Although the pathological phenotype showed characteristic GPI-less features, including abundant extracellular plaque formation, three subsequent serial passages in fully glycosylated and GPI-anchored bank vole I109 PrPC expressing transgenic mice TgVole (1×) demonstrated that the strain's distinctive rapid propagation properties were preserved. These findings suggest that neither GPI anchoring nor glycosylation are essential for maintaining CWD-vole strain properties, supporting the concept that strain characteristics are primarily encoded in the protein's misfolded structure.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Viral protein nanoparticles (Part 1): Pharmaceutical characteristics

  • Mellid Carballal, Rocío
  • Gutiérrez Gutiérrez, Sara
  • Rivas, Carmen
  • García Fuentes, Marcos
Viral protein nanoparticles fill the gap between viruses and synthetic nanoparticles. Combining advantageous properties of both systems, they have revolutionized pharmaceutical research. Virus-like particles are characterized by a structure identical to viruses but lacking genetic material. Another type of viral protein nanoparticles, virosomes, are similar to liposomes but include viral spike proteins. Both systems are effective and safe vaccine candidates capable of overcoming the disadvantages of both traditional and subunit vaccines. Besides, their particulate structure, biocompatibility, and biodegradability make them good candidates as vectors for drug and gene delivery, and for diagnostic applications. In this review, we analyze viral protein nanoparticles from a pharmaceutical perspective and examine current research focused on their development process, from production to administration. Advances in synthesis, modification and formulation of viral protein nanoparticles are critical so that large-scale production of viral protein nanoparticle products becomes viable and affordable, which ultimately will increase their market penetration in the future. We will discuss their expression systems, modification strategies, formulation, biopharmaceutical properties, and biocompatibility.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Viral protein-based nanoparticles (part 2): Pharmaceutical applications

  • Mellid Carballal, Rocío
  • Gutiérrez Gutiérrez, Sara
  • Rivas, Carmen
  • García Fuentes, Marcos
Viral protein nanoparticles (ViP NPs) such as virus-like particles and virosomes are structures halfway between viruses and synthetic nanoparticles. The biological nature of ViP NPs endows them with the biocompatibility, biodegradability, and functional properties that many synthetic nanoparticles lack. At the same time, the absence of a viral genome avoids the safety concerns of viruses. Such characteristics of ViP NPs offer a myriad of opportunities for theirapplication at several points across disease development: from prophylaxis to diagnosis and treatment. ViP NPs present remarkable immunostimulant properties, and thus the vaccination field has benefited the most from these platforms capable of overcoming the limitations of both traditional and subunit vaccines. This was reflected in the marketing authorization of several VLP- and virosome-based vaccines. Besides, ViP NPs inherit the ability of viruses to deliver their cargo to target cells. Because of that, ViP NPs are promising candidates as vectors for drug and gene delivery, and for diagnostic applications. In this review, we analyze the pharmaceutical applications of ViP NPs, describing the products that are commercially available or under clinical evaluation, but also the advances that scientists are making toward the implementation of ViP NPs in other areas of major pharmaceutical interest
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Viral protein-based nanoparticles (part 2): Pharmaceutical applications

  • Mellid-Carballal, Rocio
  • Gutierrez-Gutierrez, Sara
  • Rivas, Carmen
  • Garcia-Fuentes, Marcos
Viral protein nanoparticles (ViP NPs) such as virus-like particles and virosomes are structures halfway between viruses and synthetic nanoparticles. The biological nature of ViP NPs endows them with the biocompatibility, biodegradability, and functional properties that many synthetic nanoparticles lack. At the same time, the absence of a viral genome avoids the safety concerns of viruses. Such characteristics of ViP NPs offer a myriad of opportunities for theirapplication at several points across disease development: from prophylaxis to diagnosis and treatment. ViP NPs present remarkable immunostimulant properties, and thus the vaccination field has benefited the most from these platforms capable of overcoming the limitations of both traditional and subunit vaccines. This was reflected in the marketing authorization of several VLP- and virosome-based vaccines. Besides, ViP NPs inherit the ability of viruses to deliver their cargo to target cells. Because of that, ViP NPs are promising candidates as vectors for drug and gene delivery, and for diagnostic applications. In this review, we analyze the pharmaceutical applications of ViP NPs, describing the products that are commercially available or under clinical evaluation, but also the advances that scientists are making toward the implementation of ViP NPs in other areas of major pharmaceutical interest., This publication is part of the following grants: PID2021–124986OB-I00 (Project “IMMMA”) funded by MCIN/AEI/ 10.13039/ 501100011033 and by “ERDF A way of making Europe”; AC21_2/00046 (Project “RAIN”) funded by Health Institute Carlos III/MCIN/AEI/ 10.13039/501100011033 and by “European Union NextGenerationEU/EURONANOMED 3; PID2021–126510NB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and “ERDF A way of making Europe”; and ED431G 2019/02 grant funded by Xunta de Galicia. RMC is a recipient of a predoctoral grant from the Ministerio de Educación y FormaciónProfesional (FPU20/01525)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Viral protein nanoparticles (Part 1): Pharmaceutical characteristics

  • Mellid-Carballal, Rocio
  • Gutierrez-Gutierrez, Sara
  • Rivas, Carmen
  • Garcia-Fuentes, Marcos
Viral protein nanoparticles fill the gap between viruses and synthetic nanoparticles. Combining advantageous properties of both systems, they have revolutionized pharmaceutical research. Virus-like particles are characterized by a structure identical to viruses but lacking genetic material. Another type of viral protein nanoparticles, virosomes, are similar to liposomes but include viral spike proteins. Both systems are effective and safe vaccine candidates capable of overcoming the disadvantages of both traditional and subunit vaccines. Besides, their particulate structure, biocompatibility, and biodegradability make them good candidates as vectors for drug and gene delivery, and for diagnostic applications. In this review, we analyze viral protein nanoparticles from a pharmaceutical perspective and examine current research focused on their development process, from production to administration. Advances in synthesis, modification and formulation of viral protein nanoparticles are critical so that large-scale production of viral protein nanoparticle products becomes viable and affordable, which ultimately will increase their market penetration in the future. We will discuss their expression systems, modification strategies, formulation, biopharmaceutical properties, and biocompatibility., This publication is part of the following grants: PID2021–124986OB-I00 (Project “IMMMA”) funded by MCIN/AEI/ 10.13039/ 501100011033 and by “ERDF A way of making Europe”; AC21_2/00046 (Project “RAIN”) funded by Health Institute Carlos III/MCIN/AEI/ 10.13039/501100011033 and by “European Union NextGenerationEU/ EURONANOMED 3. Funding at the laboratory of CR is provided by PID2021–126510NB-I00 funded by MCIN/AEI/10.13039/ 501100011033 and FEDER (a way to build Europe), and by Xunta de Galicia (ED431G 2019/02). RMC is a recipient of a predoctoral grant from the Ministerio de Educación y Formación Profesional (FPU20/01525)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M.
  • Díaz‑Domínguez, Carlos M.
  • Sampedro-Torres-Quevedo, Cristina
  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Galarza-Ahumada, Josu
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Pirisinu, Laura
  • Di Bari, Michele Angelo
  • Giler, Samanta
  • Raimondi, Ilaria
  • Espinosa, Juan Carlos
  • Vanni, Ilaria
  • D’Agostino, Claudia
  • Rodríguez-Cuesta, Juan
  • Pasetto, Laura
  • Bonetto, Valentina
  • González-Martín, Nora
  • Teijeira, Susana
  • Zou, Wen-Quan
  • Geijo, Mariví
  • Torres, Juan María
  • Chiesa, Roberto
  • Sánchez‑Martín, Manuel A.
  • Nonno, Romolo
  • Requena, Jesús R.
  • Castilla, Joaquín
Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7–10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2–3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability., The present work was partially funded by five different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2023-146146NB-I00 to J.C.E. funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), UE and PID2020-117465GB-I00 granted to J.R.R., funded by MICIU/AEI/https://doi.org/10.13039/501100011033. EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to J.C. and H.E. Additional support was provided by the Instituto de Salud Carlos III (ISCIII), grant numbers AC21_2/00024 (granted to J.C), and JPND-2023–1822-108 (granted to R.C.) as part of the JPND initiative JPND-2021–650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /https://doi.org/10.13039/501100011033. E.F.-M. received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Understanding the key features of the spontaneous formation of bona fde prions through a novel methodology that enables their swift and consistent generation

  • Eraña, Hasier
  • Díaz‑Domínguez, Carlos M.
  • Charco, Jorge M.
  • Vidal, Enric
  • González‑Miranda, Ezequiel
  • Pérez‑Castro, Miguel A.
  • Piñeiro, Patricia
  • López‑Moreno, Rafael
  • Sampedro‑Torres‑Quevedo, Cristina
  • Fernández‑Veiga, Leire
  • Tasis‑Galarza, Juan
  • Lorenzo, Nuria L.
  • Santini‑Santiago, Aileen
  • Lázaro, Melisa
  • García‑Martínez, Sandra
  • Gonçalves‑Anjo, Nuno
  • San‑Juan‑Ansoleaga, Maitena
  • Galarza‑Ahumada, Josu
  • Fernández‑Muñoz, Eva
  • Giler, Samanta
  • Valle, Mikel
  • Telling, Glenn C.
  • Geijó, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Among transmissible spongiform encephalopathies or prion diseases afecting humans, sporadic forms such as spo‑ radic Creutzfeldt–Jakob disease are the vast majority. Unlike genetic or acquired forms of the disease, these idiopathic forms occur seemingly due to a random event of spontaneous misfolding of the cellular PrP (PrPC) into the patho‑ genic isoform (PrPSc). Currently, the molecular mechanisms that trigger and drive this event, which occurs in approximately one individual per million each year, remain completely unknown. Modelling this phenomenon in experimental settings is highly challenging due to its sporadic and rare occurrence. Previous attempts to model spontaneous prion misfolding in vitro have not been fully successful, as the spontaneous formation of prions is infre‑ quent and stochastic, hindering the systematic study of the phenomenon. In this study, we present the frst method that consistently induces spontaneous misfolding of recombinant PrP into bona fde prions within hours, providing unprecedented possibilities to investigate the mechanisms underlying sporadic prionopathies. By fne‑tuning the Pro‑ tein Misfolding Shaking Amplifcation method, which was initially developed to propagate recombinant prions, we have created a methodology that consistently produces spontaneously misfolded recombinant prions in 100% of the cases. Furthermore, this method gives rise to distinct strains and reveals the critical infuence of charged sur‑ faces in this process., The present work was partially funded by three different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22 and PID2020-117465GB-I00, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Effect of primary structural variation on cervid prion protein in flexibility, stability, and spontaneous misfolding propensity

  • Díaz-Domínguez, Carlos M.
  • Eraña, Hasier
  • Peccati, Francesca
  • Vidal, Enric
  • Charco, Jorge M.
  • Sampedro-Torres-Quevedo, Cristina
  • Pérez-Castro, Miguel A.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Telling, Glenn C.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Protein misfolding is central to numerous neurodegenerative disorders, collectively known as proteinopathies, which include Alzheimer's disease, Parkinson's disease, and prion diseases, among others. In many cases, specific polymorphisms of the proteins associated with these diseases influence their misfolding. However, the precise ways in which these polymorphisms affect protein integrity and how they contribute to misfolding propensity remain unclear. In the case of prion diseases, they are caused by prions or PrPSc, the misfolded isoforms of the cellular prion protein (PrPC). Chronic Wasting Disease (CWD) is a prion disease that affects cervids and can exhibit lymphotropic properties, making it the most widespread proteinopathy. For that reason, cervid PrPs and their polymorphisms have been extensively studied. To better understand the role of these polymorphisms, we analyzed 45 cervid PrP variants to assess their effects on flexibility, stability, and spontaneous misfolding propensity. The cervid variants were expressed as recombinant PrP in E. coli and were analyzed for thermal stability using circular dichroism. Additionally, the rec-PrPs served as substrates for Protein Misfolding Shaking Amplification (PMSA), enabling assessment of each variant's spontaneous misfolding propensity. This process led to the formation of bona fide prions, as confirmed by inoculation of one of the resulting conformers into transgenic mice expressing bank vole PrP. In parallel, molecular dynamics simulations were conducted to analyze the structural flexibility of the variants. While differences in protein flexibility were observed, no correlation was detected among flexibility, thermal stability, and the observed variable spontaneous misfolding propensity, suggesting that these properties are independent parameters., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22, and PID2020-117465GB-I00, funded by MCIN/AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). Also funded by MCIN/AEI /10.13039/501100011033, F.P. and G.J.O. were provided with the grants RYC2022-036457-I and PID2021-125946OB-I00, respectively. EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, as part of a grant from the European Joint Program for Neurodegenerative Research (JPND) JPND-2021-650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cofactors facilitate bona fide prion misfolding in vitro but are not necessary for the infectivity of recombinant murine prions

  • Pérez-Castro, Miguel Ángel
  • Eraña, Hasier
  • Vidal, Enric
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Gonçalves-Anjo, Nuno
  • Galarza-Ahumada, Josu
  • Díaz-Domínguez, Carlos M.
  • Piñeiro, Patricia
  • González-Miranda, Ezequiel
  • Giler, Samanta
  • Telling, Glenn
  • Sánchez-Martín, Manuel A.
  • Garrido, Joseba
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases, particularly sporadic cases, pose a challenge due to their complex nature and heterogeneity. The underlying mechanism of the spontaneous conversion from PrPC to PrPSc, the hallmark of prion diseases, remains elusive. To shed light on this process and the involvement of cofactors, we have developed an in vitro system that faithfully mimics spontaneous prion misfolding using minimal components. By employing this PMSA methodology and introducing an isoleucine residue at position 108 in mouse PrP, we successfully generated recombinant murine prion strains with distinct biochemical and biological properties. Our study aimed to explore the influence of a polyanionic cofactor in modulating strain selection and infectivity in de novo-generated synthetic prions. These results not only validate PMSA as a robust method for generating diverse bona fide recombinant prions but also emphasize the significance of cofactors in shaping specific prion conformers capable of crossing species barriers. Interestingly, once these conformers are established, our findings suggest that cofactors are not necessary for their infectivity. This research provides valuable insights into the propagation and maintenance of the pathobiological features of cross-species transmissible recombinant murine prion and highlights the intricate interplay between cofactors and prion strain characteristics., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2020-117465GB-I00 granted to J.R.R., funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027) granted to J.C. and H.E. Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, granted to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /10.13039/501100011033. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Screening Strategies to Improve Early Diagnosis in Endometrial Cancer

  • De la Calle Fuentes, Irene
  • Baulies, Sonia
  • Cabrera, Silvia
  • Gil-Moreno, Antonio
  • Colás Ortega, Eva
Diagnosis; Endometrial cancer; Screening, Diagnòstic; Càncer d'endometri; Cribratge, Diagnóstico; Cáncer de endometrio; Cribado, Endometrial cancer is the most common gynecological malignancy in high-income countries and the sixth most common cancer in women. Overall incidence has risen in the last few decades as a consequence of the increase in the prevalence of its risk factors, mainly obesity and the aging of the population, and although diagnoses have increased across all age groups, the incidence rates have doubled in women under the age of 40 years. The survival rates of endometrial cancer are highly dependent on its stage at diagnosis, bringing to the fore the importance of early diagnosis. The aim of a screening strategy in this type of tumor should be to detect the disease in the pre-invasive or early stage (before developing myometrial invasion), which would improve cure rates, reduce the morbidity associated with aggressive treatment and offer uterus-sparing management options for younger women. The ideal screening tool in this scenario would be a minimally invasive, inexpensive and easy-to-perform test or auto-test, which could be implemented in a routine gynecologic checkup of patients at-risk or in the general adult population. In this comprehensive review, we aim to define the populations at higher risk of developing endometrial cancer, to assess the performance of current diagnostic tools when used in a screening setting and to discuss the accuracy of new molecular screening strategies., This research was funded by: Instituto de Salud Carlos III (ISCIII) grant number PI20/00644, PI23/01470, IFI19/00029 to E.C.R., IFI22/00019 to I.C., and CP22/00147 to E.C.; Grant number AC21_2/00030; Ministerio de Ciencia, Innovación y Universidades through a Proyectos en Colaboración Publico-Privada 2021 grant number CPP2022-009817, co-financed by the European Regional Development Fund (FEDER); Generalitat de Catalunya: SGR 2021 01157; CIBERONC network grant number CB16/12/00328; European Comission by Era PerMed project financed by AECC (grant number PERME212443COLA).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A Protein Misfolding Shaking Amplificationbased method for the spontaneous generation of hundreds of bona fide prions

  • Eraña, Hasier
  • Sampedro-Torres-Quevedo, Cristina
  • Charco, Jorge M.
  • Díaz-Domínguez, Carlos M.
  • Peccati, Francesca
  • San-Juan-Ansoleaga, Maitena
  • Vidal, Enric
  • Gonçalves-Anjo, Nuno
  • Pérez-Castro, Miguel A.
  • González-Miranda, Ezequiel
  • Piñeiro, Patricia
  • Fernández-Veiga, Leire
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • Perez de Nanclares, Guiomar
  • Telling, Glenn
  • Geijo, Mariví
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Prion diseases are a group of rapidly progressing neurodegenerative disorders caused by the misfolding of the endogenous prion protein (PrPC) into a pathogenic form (PrPSc). This process, despite being the central event underlying these disorders, remains largely unknown at a molecular level, precluding the prediction of new potential outbreaks or interspecies transmission incidents. In this work, we present a method to generate bona fide recombinant prions de novo, allowing a comprehensive analysis of protein misfolding across a wide range of prion proteins from mammalian species. We study more than 380 different prion proteins from mammals and classify them according to their spontaneous misfolding propensity and their conformational variability. This study aims to address fundamental questions in the prion research field such as defining infectivity determinants, interspecies transmission barriers or the structural influence of specific amino acids and provide invaluable information for future diagnosis and therapy applications., The authors would like to thank the following for their support: IKERBasque foundation, personnel from vivarium, IT service (in particular to Sara Gómez Ramos for her assistance with the PrPdex webpage), maintenance departments of CIC bioGUNE, Neiker and IRTA-CReSA. The authors would also like to acknowledge the work from past laboratory members of the Prion Research Lab from CIC bioGUNE, that despite not directly involved in the manuscript have contributed along the years to the development of all the methods and techniques currently used in the laboratory (specially to Tomás Barrio and Leire Hervá for their efforts at the initial and end stages of the work, respectively). Finally, we would like to thank Jesús R. Requena for always useful scientific discussions and advice. The present work was partially funded by different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010BC22, PID2021-125946OB-I00 and IJC2020-045506-I, funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021- 001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Conservation of strain properties of bank vole-adapted chronic wasting disease in the absence of glycosylation and membrane anchoring

  • Vidal, Enric
  • Eraña, Hasier
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Ordóñez, Montserrat
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Telling, Glenn C.
  • Sánchez-Martín, Manuel A.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion disease phenotypes (prion strains) are primarily determined by the specific misfolded conformation of the cellular prion protein (PrPC). However, post-translational modifications, including glycosyl phosphatidyl inositol (GPI) membrane anchoring and glycosylation, may influence strain characteristics. We investigated whether these modifications are essential for maintaining the unique properties of bank vole-adapted Chronic Wasting Disease (CWD-vole), the fastest known prion strain. Using a novel transgenic mouse model expressing I109 bank vole PrPC lacking the GPI anchor and largely devoid of glycans, we performed serial passages of CWD-vole prions. Despite elongated initial incubation periods, the strain maintained 100 % attack rate through three passages. Although the pathological phenotype showed characteristic GPI-less features, including abundant extracellular plaque formation, three subsequent serial passages in fully glycosylated and GPI-anchored bank vole I109 PrPC expressing transgenic mice TgVole (1×) demonstrated that the strain's distinctive rapid propagation properties were preserved. These findings suggest that neither GPI anchoring nor glycosylation are essential for maintaining CWD-vole strain properties, supporting the concept that strain characteristics are primarily encoded in the protein's misfolded structure., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 and PID2021-1222010B-C22, and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024 as member of a JPND grant JPND-2021-650-130. Additionally, CICbioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. Transgenic Facility, directed by M.A. S-M, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Toward Next Generation Lateral Flow Assays, Integration of Nanomaterials

  • Sena-Torralba, Amadeo|||0000-0003-1340-1383
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Parolo, Claudio|||0000-0001-9481-4408
  • Piper, Andrew|||0000-0002-1208-8009
  • Merkoçi, Arben|||0000-0003-2486-8085
Lateral flow assays (LFAs) are currently the most used point-of-care sensors for both diagnostic (e.g., pregnancy test, COVID-19 monitoring) and environmental (e.g., pesticides and bacterial monitoring) applications. Although the core of LFA technology was developed several decades ago, in recent years the integration of novel nanomaterials as signal transducers or receptor immobilization platforms has brought improved analytical capabilities. In this Review, we present how nanomaterial-based LFAs can address the inherent challenges of point-of-care (PoC) diagnostics such as sensitivity enhancement, lowering of detection limits, multiplexing, and quantification of analytes in complex samples. Specifically, we highlight the strategies that can synergistically solve the limitations of current LFAs and that have proven commercial feasibility. Finally, we discuss the barriers toward commercialization and the next generation of LFAs.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Potential biomarkers and their recent applications ofr point-of-care biosensors for the diagnosis of malaria

  • Karadurmus, Leyla
  • CETINKAYA, Ahmet
  • Kocabay, Pinar
  • Ben Jaballah, Menyar
  • OZKAN, Sibel
  • Baldrich, Eva
Malaria; Biosensors; Biomarkers, Malària; Biosensors; Biomarcadors, Malaria; Biosensores; Biomarcadores, Malaria remains to be one of the deadliest infectious illnesses and is especially common in underdeveloped and developing countries. Recent advances (2022–2025) in biosensor engineering, nanomaterials, and microfluidic automation have significantly expanded the capabilities of point-of-care diagnostic technologies for malaria. With the guidance of the World Health Organization (WHO) and the international community, malaria-endemic lands have achieved measurable advances in disease control and elimination. Globally, we are witnessing an increase in cases of clinically atypical malaria and asymptomatic carriers, which contributes to misdiagnosis and missed diagnosis. Other challenges include climate change, socioeconomic inequality, limited healthcare infrastructure, the emergence of new vector species, and increasing resistance to antimalarial drugs and insecticides. This shows that additional efforts will be needed if malaria is to be eradicated. Creating simple, practical, and affordable integrated biosensors is essential to diagnose early-stage malaria. In this context, one of the main challenges is converting complex biosensor techniques into affordable point-of-care testing (POCT) technologies that could be employed close to the patient without requiring skilled professionals or special infrastructures. Unlike recent reviews that primarily focus either on biomarker discovery or broadly on POC technologies, this work provides a comparative and mechanistic evaluation of electrochemical, optical, and piezoelectric biosensors, emphasizing primary research articles. Particular attention is given to signal transduction mechanisms, analytical trade-offs, microfluidic integration strategies, and real-world deployability considerations. This review gives general information about the biomarkers used for malaria diagnosis and summarizes some prominent examples of biosensors described in previous studies for malaria detection POCT making use of different transduction formats. The work finishes with some general conclusions, demanding to progress the design of portable point-of-care diagnostic technologies and further research to achieve sensitive quantification of biomarker panels as the key to the future of malaria detection and global control., Open access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK). This work was conducted within the framework of the “Quantitative and storage-stable point-of-care diagnostic device (QUPID)” EuroNanoMed-JTC2021-110 project, provided funding from TÜBİTAK Project Number 221N359, ISCIII Project AC21_2/00021. The authors appreciate the funding received from THE SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF TÜRKİYE (TÜBİTAK), Project Number 221N359.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Screening Strategies to Improve Early Diagnosis in Endometrial Cancer

  • De la Calle Fuentes, Irene
  • Baulies, Sonia
  • Cabrera, Silvia
  • Gil-Moreno, Antonio
  • Colás Ortega, Eva
Diagnosis; Endometrial cancer; Screening, Diagnòstic; Càncer d'endometri; Cribratge, Diagnóstico; Cáncer de endometrio; Cribado, Endometrial cancer is the most common gynecological malignancy in high-income countries and the sixth most common cancer in women. Overall incidence has risen in the last few decades as a consequence of the increase in the prevalence of its risk factors, mainly obesity and the aging of the population, and although diagnoses have increased across all age groups, the incidence rates have doubled in women under the age of 40 years. The survival rates of endometrial cancer are highly dependent on its stage at diagnosis, bringing to the fore the importance of early diagnosis. The aim of a screening strategy in this type of tumor should be to detect the disease in the pre-invasive or early stage (before developing myometrial invasion), which would improve cure rates, reduce the morbidity associated with aggressive treatment and offer uterus-sparing management options for younger women. The ideal screening tool in this scenario would be a minimally invasive, inexpensive and easy-to-perform test or auto-test, which could be implemented in a routine gynecologic checkup of patients at-risk or in the general adult population. In this comprehensive review, we aim to define the populations at higher risk of developing endometrial cancer, to assess the performance of current diagnostic tools when used in a screening setting and to discuss the accuracy of new molecular screening strategies., This research was funded by: Instituto de Salud Carlos III (ISCIII) grant number PI20/00644, PI23/01470, IFI19/00029 to E.C.R., IFI22/00019 to I.C., and CP22/00147 to E.C.; Grant number AC21_2/00030; Ministerio de Ciencia, Innovación y Universidades through a Proyectos en Colaboración Publico-Privada 2021 grant number CPP2022-009817, co-financed by the European Regional Development Fund (FEDER); Generalitat de Catalunya: SGR 2021 01157; CIBERONC network grant number CB16/12/00328; European Comission by Era PerMed project financed by AECC (grant number PERME212443COLA).
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Understanding the key features of the spontaneous formation of bona fde prions through a novel methodology that enables their swift and consistent generation

  • Eraña, Hasier
  • Díaz‑Domínguez, Carlos M.
  • Charco, Jorge M.
  • Vidal, Enric
  • González‑Miranda, Ezequiel
  • Pérez‑Castro, Miguel A.
  • Piñeiro, Patricia
  • López‑Moreno, Rafael
  • Sampedro‑Torres‑Quevedo, Cristina
  • Fernández‑Veiga, Leire
  • Tasis‑Galarza, Juan
  • Lorenzo, Nuria L.
  • Santini‑Santiago, Aileen
  • Lázaro, Melisa
  • García‑Martínez, Sandra
  • Gonçalves‑Anjo, Nuno
  • San‑Juan‑Ansoleaga, Maitena
  • Galarza‑Ahumada, Josu
  • Fernández‑Muñoz, Eva
  • Giler, Samanta
  • Valle, Mikel
  • Telling, Glenn C.
  • Geijó, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Among transmissible spongiform encephalopathies or prion diseases afecting humans, sporadic forms such as spo‑ radic Creutzfeldt–Jakob disease are the vast majority. Unlike genetic or acquired forms of the disease, these idiopathic forms occur seemingly due to a random event of spontaneous misfolding of the cellular PrP (PrPC) into the patho‑ genic isoform (PrPSc). Currently, the molecular mechanisms that trigger and drive this event, which occurs in approximately one individual per million each year, remain completely unknown. Modelling this phenomenon in experimental settings is highly challenging due to its sporadic and rare occurrence. Previous attempts to model spontaneous prion misfolding in vitro have not been fully successful, as the spontaneous formation of prions is infre‑ quent and stochastic, hindering the systematic study of the phenomenon. In this study, we present the frst method that consistently induces spontaneous misfolding of recombinant PrP into bona fde prions within hours, providing unprecedented possibilities to investigate the mechanisms underlying sporadic prionopathies. By fne‑tuning the Pro‑ tein Misfolding Shaking Amplifcation method, which was initially developed to propagate recombinant prions, we have created a methodology that consistently produces spontaneously misfolded recombinant prions in 100% of the cases. Furthermore, this method gives rise to distinct strains and reveals the critical infuence of charged sur‑ faces in this process., The present work was partially funded by three different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22 and PID2020-117465GB-I00, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Overexpression of bank vole PrP(I109) in mice induces a spontaneous atypical prion disease with sex-dependent onset, early NfL elevation, and universal prion strain permissiveness

  • Eraña, Hasier
  • Vidal, Enric
  • Fernández-Borges, Natalia
  • Charco, Jorge M.
  • Díaz‑Domínguez, Carlos M.
  • Sampedro-Torres-Quevedo, Cristina
  • San-Juan-Ansoleaga, Maitena
  • Fernández-Muñoz, Eva
  • Galarza-Ahumada, Josu
  • Pérez-Castro, Miguel Ángel
  • Gonçalves-Anjo, Nuno
  • Piñeiro, Patricia
  • Pirisinu, Laura
  • Di Bari, Michele Angelo
  • Giler, Samanta
  • Raimondi, Ilaria
  • Espinosa, Juan Carlos
  • Vanni, Ilaria
  • D’Agostino, Claudia
  • Rodríguez-Cuesta, Juan
  • Pasetto, Laura
  • Bonetto, Valentina
  • González-Martín, Nora
  • Teijeira, Susana
  • Zou, Wen-Quan
  • Geijo, Mariví
  • Torres, Juan María
  • Chiesa, Roberto
  • Sánchez‑Martín, Manuel A.
  • Nonno, Romolo
  • Requena, Jesús R.
  • Castilla, Joaquín
Transgenic mice overexpressing bank vole prion protein with the isoleucine 109 polymorphism, TgVole(I109)4x, develop spontaneous neurodegenerative disease with sex-dependent onset, averaging 170 days in females and 200 days in males at terminal stage. The clinical and pathological features closely resemble Gerstmann-Sträussler-Scheinker syndrome (GSS), with characteristic ataxia, dysmetria, kyphosis, and prominent PrP plaques. Biochemical analysis reveals an atypical prion protein banding pattern with a distinctive low molecular weight band (7–10 kDa) following proteinase K digestion, similar to other atypical prion diseases such as small ruminants atypical scrapie (AS). Importantly, these spontaneously generated prions are highly infectious when passaged to mice expressing the same I109 polymorphism as well as to wild bank voles carrying the I109 polymorphism, but not to models expressing the methionine variant at this position, demonstrating the critical role of this specific polymorphism in atypical prion propagation. Temporal analysis reveals that infectious prions emerge significantly (2–3 months) before clinical signs appear, offering important insights into the pre-clinical phase of prion diseases. Serum neurofilament light chain levels increase significantly at 80 days of age, approximately 100 days before clinical onset, providing a wide therapeutic window with a reliable biomarker. The TgVole(I109)4× model exhibits extraordinary versatility in propagating diverse prion strains, showing remarkable susceptibility to atypical prions (including GSS and AS) with exceptionally short incubation periods, while maintaining the ability to efficiently propagate classical and recombinant prion strains. We present here a thoroughly characterized transgenic mouse model that spontaneously develops an atypical, bona fide prion disease with sex-related differences in disease onset. This model offers valuable insights into spontaneous and atypical prionopathies while demonstrating exceptional versatility for studying diverse prion strains and potential utility for evaluating therapeutic interventions when used with appropriate study designs that account for individual variability., The present work was partially funded by five different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2024-160022OB-I00, PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2023-146146NB-I00 to J.C.E. funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), UE and PID2020-117465GB-I00 granted to J.R.R., funded by MICIU/AEI/https://doi.org/10.13039/501100011033. EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027) granted to J.C. and H.E. Additional support was provided by the Instituto de Salud Carlos III (ISCIII), grant numbers AC21_2/00024 (granted to J.C), and JPND-2023–1822-108 (granted to R.C.) as part of the JPND initiative JPND-2021–650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /https://doi.org/10.13039/501100011033. E.F.-M. received funding from Fundación Tatiana Pérez de Guzmán el Bueno, grant BN661-FTPGB-2023. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. This work also received funding from the Creutzfeldt-Jakob Disease Foundation—2022. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

A Protein Misfolding Shaking Amplificationbased method for the spontaneous generation of hundreds of bona fide prions

  • Eraña, Hasier
  • Sampedro-Torres-Quevedo, Cristina
  • Charco, Jorge M.
  • Díaz-Domínguez, Carlos M.
  • Peccati, Francesca
  • San-Juan-Ansoleaga, Maitena
  • Vidal, Enric
  • Gonçalves-Anjo, Nuno
  • Pérez-Castro, Miguel A.
  • González-Miranda, Ezequiel
  • Piñeiro, Patricia
  • Fernández-Veiga, Leire
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • Perez de Nanclares, Guiomar
  • Telling, Glenn
  • Geijo, Mariví
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Prion diseases are a group of rapidly progressing neurodegenerative disorders caused by the misfolding of the endogenous prion protein (PrPC) into a pathogenic form (PrPSc). This process, despite being the central event underlying these disorders, remains largely unknown at a molecular level, precluding the prediction of new potential outbreaks or interspecies transmission incidents. In this work, we present a method to generate bona fide recombinant prions de novo, allowing a comprehensive analysis of protein misfolding across a wide range of prion proteins from mammalian species. We study more than 380 different prion proteins from mammals and classify them according to their spontaneous misfolding propensity and their conformational variability. This study aims to address fundamental questions in the prion research field such as defining infectivity determinants, interspecies transmission barriers or the structural influence of specific amino acids and provide invaluable information for future diagnosis and therapy applications., The authors would like to thank the following for their support: IKERBasque foundation, personnel from vivarium, IT service (in particular to Sara Gómez Ramos for her assistance with the PrPdex webpage), maintenance departments of CIC bioGUNE, Neiker and IRTA-CReSA. The authors would also like to acknowledge the work from past laboratory members of the Prion Research Lab from CIC bioGUNE, that despite not directly involved in the manuscript have contributed along the years to the development of all the methods and techniques currently used in the laboratory (specially to Tomás Barrio and Leire Hervá for their efforts at the initial and end stages of the work, respectively). Finally, we would like to thank Jesús R. Requena for always useful scientific discussions and advice. The present work was partially funded by different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010BC22, PID2021-125946OB-I00 and IJC2020-045506-I, funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021- 001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Cofactors facilitate bona fide prion misfolding in vitro but are not necessary for the infectivity of recombinant murine prions

  • Pérez-Castro, Miguel Ángel
  • Eraña, Hasier
  • Vidal, Enric
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Gonçalves-Anjo, Nuno
  • Galarza-Ahumada, Josu
  • Díaz-Domínguez, Carlos M.
  • Piñeiro, Patricia
  • González-Miranda, Ezequiel
  • Giler, Samanta
  • Telling, Glenn
  • Sánchez-Martín, Manuel A.
  • Garrido, Joseba
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion diseases, particularly sporadic cases, pose a challenge due to their complex nature and heterogeneity. The underlying mechanism of the spontaneous conversion from PrPC to PrPSc, the hallmark of prion diseases, remains elusive. To shed light on this process and the involvement of cofactors, we have developed an in vitro system that faithfully mimics spontaneous prion misfolding using minimal components. By employing this PMSA methodology and introducing an isoleucine residue at position 108 in mouse PrP, we successfully generated recombinant murine prion strains with distinct biochemical and biological properties. Our study aimed to explore the influence of a polyanionic cofactor in modulating strain selection and infectivity in de novo-generated synthetic prions. These results not only validate PMSA as a robust method for generating diverse bona fide recombinant prions but also emphasize the significance of cofactors in shaping specific prion conformers capable of crossing species barriers. Interestingly, once these conformers are established, our findings suggest that cofactors are not necessary for their infectivity. This research provides valuable insights into the propagation and maintenance of the pathobiological features of cross-species transmissible recombinant murine prion and highlights the intricate interplay between cofactors and prion strain characteristics., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 granted to J.C., PID2021-1222010B-C22 granted to E.V., and PID2020-117465GB-I00 granted to J.R.R., funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65% by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027) granted to J.C. and H.E. Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, granted to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S granted to J.C., also funded by Ministerio de Ciencia e Innovación/AEI /10.13039/501100011033. Transgenic Facility, directed by M.A.S.-M., is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Effect of primary structural variation on cervid prion protein in flexibility, stability, and spontaneous misfolding propensity

  • Díaz-Domínguez, Carlos M.
  • Eraña, Hasier
  • Peccati, Francesca
  • Vidal, Enric
  • Charco, Jorge M.
  • Sampedro-Torres-Quevedo, Cristina
  • Pérez-Castro, Miguel A.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Telling, Glenn C.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Protein misfolding is central to numerous neurodegenerative disorders, collectively known as proteinopathies, which include Alzheimer's disease, Parkinson's disease, and prion diseases, among others. In many cases, specific polymorphisms of the proteins associated with these diseases influence their misfolding. However, the precise ways in which these polymorphisms affect protein integrity and how they contribute to misfolding propensity remain unclear. In the case of prion diseases, they are caused by prions or PrPSc, the misfolded isoforms of the cellular prion protein (PrPC). Chronic Wasting Disease (CWD) is a prion disease that affects cervids and can exhibit lymphotropic properties, making it the most widespread proteinopathy. For that reason, cervid PrPs and their polymorphisms have been extensively studied. To better understand the role of these polymorphisms, we analyzed 45 cervid PrP variants to assess their effects on flexibility, stability, and spontaneous misfolding propensity. The cervid variants were expressed as recombinant PrP in E. coli and were analyzed for thermal stability using circular dichroism. Additionally, the rec-PrPs served as substrates for Protein Misfolding Shaking Amplification (PMSA), enabling assessment of each variant's spontaneous misfolding propensity. This process led to the formation of bona fide prions, as confirmed by inoculation of one of the resulting conformers into transgenic mice expressing bank vole PrP. In parallel, molecular dynamics simulations were conducted to analyze the structural flexibility of the variants. While differences in protein flexibility were observed, no correlation was detected among flexibility, thermal stability, and the observed variable spontaneous misfolding propensity, suggesting that these properties are independent parameters., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22, and PID2020-117465GB-I00, funded by MCIN/AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). Also funded by MCIN/AEI /10.13039/501100011033, F.P. and G.J.O. were provided with the grants RYC2022-036457-I and PID2021-125946OB-I00, respectively. EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, as part of a grant from the European Joint Program for Neurodegenerative Research (JPND) JPND-2021-650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Conservation of strain properties of bank vole-adapted chronic wasting disease in the absence of glycosylation and membrane anchoring

  • Vidal, Enric
  • Eraña, Hasier
  • Charco, Jorge M.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Ordóñez, Montserrat
  • Fernández-Muñoz, Eva
  • San-Juan-Ansoleaga, Maitena
  • Telling, Glenn C.
  • Sánchez-Martín, Manuel A.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Castilla, Joaquín
Prion disease phenotypes (prion strains) are primarily determined by the specific misfolded conformation of the cellular prion protein (PrPC). However, post-translational modifications, including glycosyl phosphatidyl inositol (GPI) membrane anchoring and glycosylation, may influence strain characteristics. We investigated whether these modifications are essential for maintaining the unique properties of bank vole-adapted Chronic Wasting Disease (CWD-vole), the fastest known prion strain. Using a novel transgenic mouse model expressing I109 bank vole PrPC lacking the GPI anchor and largely devoid of glycans, we performed serial passages of CWD-vole prions. Despite elongated initial incubation periods, the strain maintained 100 % attack rate through three passages. Although the pathological phenotype showed characteristic GPI-less features, including abundant extracellular plaque formation, three subsequent serial passages in fully glycosylated and GPI-anchored bank vole I109 PrPC expressing transgenic mice TgVole (1×) demonstrated that the strain's distinctive rapid propagation properties were preserved. These findings suggest that neither GPI anchoring nor glycosylation are essential for maintaining CWD-vole strain properties, supporting the concept that strain characteristics are primarily encoded in the protein's misfolded structure., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21 and PID2021-1222010B-C22, and co-financed by the European Regional Development Fund (ERDF). EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021–2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024 as member of a JPND grant JPND-2021-650-130. Additionally, CICbioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. Transgenic Facility, directed by M.A. S-M, is supported by Instituto de Salud Carlos III (ISCIII), co-funded by the European Union grant PT23/00123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion